Pyrazoloquinolines

US8802712B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Thomas Fuchss · Bensheim, DE
• Werner Mederski · Zwingenberg, DE
• Frank Zenke · Darmstadt, DE

Key dates

• Filing date: Jun 24, 2011
• Grant date: Aug 12, 2014
• Expiry date: Jun 24, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N9/99
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to compounds of the formulae (I), (II) and (III), and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumours, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I) by reaction of compounds of the formula (II) or (III) and optionally conversion of a base or acid of the compounds of the formula (I) into one of its salts